NCT02652091 - Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction | Biotech Hunter

Enrollment

146

Participants

Timeline

Start Date

February 5, 2016

Primary Completion Date

August 11, 2017

Study Completion Date

September 13, 2017

Conditions

Multiple Sclerosis, Relapsing-Remitting

Interventions

DRUG

Interferon beta-1b (Betaseron, BAY86-5046)

Applied via the BETACONNECT device. Dose as prescribed by physician.

DEVICE

BETACONNECT device

Used to apply Betaseron.

Trial Locations (23)

10306

Staten Island

17543

Lititz

19004

Bala-Cynwyd

20759

Fulton

22031

Fairfax

33428

Boca Raton

33609

Tampa

34653

New Port Richey

35058

Cullman

37064

Franklin

37212

Nashville

38104

Memphis

48427

Deckerville

63131

St Louis

78681

Round Rock

79430

Lubbock

97504

Medford

30309-1465

Atlanta

02035

Foxborough

08084

Stratford

07666

Teaneck

Unknown

Medford

Virginia Beach